AT1 receptor
26 drugs Cardiovascular
6
approved indications
26
Approved Drugs
17
Companies
14
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (17 companies)
✓ All 26 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (14 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novartis 4 drugs
COSETTE 3 drugs
Merck 2 drugs
By Therapeutic Area
Cardiovascular 22 drugs
Other 4 drugs
Drugs by Company PRO
Novartis 4 drugs
COSETTE 3 drugs
ANI PHARMS 2 drugs
AZURITY 2 drugs
ALEMBIC 2 drugs
GLENMARK PHARMS LTD 1 drug
SCIENTURE 1 drug
MACLEODS PHARMS LTD 1 drug
+ 7 more companies
By Therapeutic Area
Cardiovascular 22 drugs
COZAAR, DIOVAN, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL +18 more
Other 4 drugs
ENTRESTO, FILSPARI, VALSARTAN AND HYDROCHLOROTHIAZIDE, TRIBENZOR
Indications Treated
HypertensionStrokeMyocardial InfarctionHeart FailureLeft Ventricular Systolic DysfunctionDiabetic NephropathyImmunoglobulin A NephropathyLeft Ventricular HypertrophyLeft Ventricular FailureLeft Ventricular DysfunctionType 2 DiabetesProteinuriaChronic heart failure in adultsSymptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older
All Drugs Targeting AT1 receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| COZAAR Top | Merck | 1995 | 6 | Cardiovascular |
| DIOVAN | Novartis | 1996 | 5 | Cardiovascular |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | Teva | 2016 | 3 | Cardiovascular |
| OLMESARTAN MEDOXOMIL | GLENMARK PHARMS LTD | 2016 | 3 | Cardiovascular |
| ARBLI | SCIENTURE | 2025 | 3 | Cardiovascular |
| DIOVAN HCT | Novartis | 1998 | 3 | Cardiovascular |
| HYZAAR | Merck | 1995 | 3 | Cardiovascular |
| CANDESARTAN CILEXETIL | MACLEODS PHARMS LTD | 2013 | 2 | Cardiovascular |
| SACUBITRIL AND VALSARTAN | TORRENT | 2024 | 2 | Cardiovascular |
| AVAPRO | Sanofi | 1997 | 2 | Cardiovascular |
| ENTRESTO SPRINKLE | Novartis | 2024 | 2 | Cardiovascular |
| ATACAND | ANI PHARMS | 1998 | 2 | Cardiovascular |
| AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE | ALKEM LABS LTD | 2025 | 2 | Cardiovascular |
| ENTRESTO | Novartis | 2015 | 2 | |
| EDARBYCLOR | AZURITY | 2011 | 2 | Cardiovascular |
| TELMISARTAN | ALEMBIC | 2014 | 1 | Cardiovascular |
| OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | ALEMBIC | 2016 | 1 | Cardiovascular |
| FILSPARI | TRAVERE | 2023 | 1 | |
| EDARBI | AZURITY | 2011 | 1 | Cardiovascular |
| CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | ZYDUS LIFESCIENCES | 2012 | 1 | Cardiovascular |
| ATACAND HCT | ANI PHARMS | 2000 | 1 | Cardiovascular |
| BENICAR | COSETTE | 2002 | 1 | Cardiovascular |
| BENICAR HCT | COSETTE | 2003 | 1 | Cardiovascular |
| MICARDIS HCT | Boehringer Ingelheim | 2000 | 1 | Cardiovascular |
| VALSARTAN AND HYDROCHLOROTHIAZIDE | Lupin | 2012 | - | |
| TRIBENZOR | COSETTE | 2010 | - |